Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-01-17 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) for Tianyu Bio-Technology Co., Ltd. It provides preliminary estimated net profit figures for the full fiscal year 2024, explicitly stating that the data is unaudited and preliminary, and that the final audited financial data will be disclosed in the formal 2024 annual report. The document is short (1569 characters) and serves as an earnings forecast rather than a full financial report. It does not contain actual audited financial statements or detailed financial analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts. FY 2024
2025-01-17 Chinese
关于控股股东所持股份解除质押及再质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge, release, and re-pledge of shares held by the controlling shareholders of the company. It details the number of shares pledged, released, and the related percentages of total share capital. It also discusses the absence of risks such as forced liquidation and the impact of the pledge on the company's operations and control. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging activities by major shareholders, which fits the category of Major Shareholding Notification (MRQ). The document length is 2461 characters, which is typical for such announcements and not a full report or earnings release. Therefore, the correct classification is MRQ with high confidence.
2025-01-17 Chinese
2024年第四季度主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (445 characters) presenting the company's main operating data for the fourth quarter of 2024, specifically sales and inventory volumes of livestock. It explicitly states that the data is unaudited and is for investor reference only. There are no detailed financial statements, comprehensive analysis, or management discussion. The document is not a full quarterly or annual report but a brief operational data update. Given its brevity and nature, it fits best as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER).
2025-01-14 Chinese
关于公司2024年度对外担保预计的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's external guarantees for the year 2024, detailing the guarantee amounts, the parties involved, internal decision procedures, and the board's opinions. It includes financial figures related to the guarantees but does not present a comprehensive financial report or detailed financial statements for a fiscal period. The document is relatively short (2801 characters) and focuses on a specific corporate action (external guarantees) rather than a full financial or management report. It is not an annual or interim report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits best with a Regulatory Filing (RNS) as it is a formal disclosure of a corporate guarantee event and related information that does not fit other specific categories.
2025-01-10 Chinese
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting of shareholders (临时股东大会) for Tianyu Bio-Technology Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings, or report content. It is an announcement informing shareholders about the meeting and how to participate, including proxy voting instructions. The document length is about 3,000 characters, which is short and consistent with a meeting notice rather than a full report or voting results. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2025-01-06 Chinese
关于2024年度为合作养殖农户提供担保预计的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tianyu Bio-Technology Co., Ltd. regarding the progress of guarantees provided for cooperative farming households in 2024. It details the guarantee amount, the parties involved, internal decision procedures, and the rationale for the guarantee. The document is relatively short (2324 characters) and focuses on a specific financial guarantee update rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis. It is a regulatory announcement about a financing-related guarantee activity, but not a capital raising or financing update per se. Given the nature of the content and the length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-06 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.